Stéphane Bancel, Moderna CEO (Joel Saget/AFP via Getty Images)

Up­dat­ed: Mod­er­na rounds out 2022 with $18.4B in vac­cine sales, boosts R&D bud­get for 2023

Mod­er­na CEO Stéphane Ban­cel is revving the en­gines go­ing in­to 2023, with a whop­ping $4.5 bil­lion R&D bud­get and a new pri­or­i­ty re­view vouch­er.

The com­pa­ny’s full-year sales to­taled $18.4 bil­lion, it an­nounced on Mon­day, falling shy of the chief ex­ec­u­tive’s pre­vi­ous $21 bil­lion pro­jec­tions. Ban­cel cit­ed de­liv­ery de­lays, short-term sup­ply short­ages and a “very com­plex third quar­ter from a man­u­fac­tur­ing stand­point” up­on low­er­ing the guid­ance last quar­ter, while promis­ing that the com­pa­ny is “in a much bet­ter place” for 2023.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.